Araris Biotech
Basel, CH · 6 known investors
Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy. The platform generates stable, homogenous ADCs for oncology applications without requiring antibody re-engineering.
BiotechMedical Devices
Founders & leadership
DG
Dragan GrabulovskiCo-founder and CEO
PS
Philipp SpycherCo-founder and Chief Scientific Officer
IA
Isabella Attinger-TollerCo-founder